LeBlanc Jeff 4

What Happened

• Jeff LeBlanc, Chief Financial Officer of Klotho Neurosciences (KLTO), received a grant of 2,500,000 shares on 2026-03-04. The filing lists this as an award/acquisition (code A); no purchase price or total dollar value is reported (N/A).
• This is an equity award (compensation/retention tool) rather than an open-market purchase or sale, so it does not represent an immediate buy or sell signal.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (filed within the usual 2-business-day reporting window).
• Transaction type/code: Award/Grant (A); price reported as N/A (no cash paid).
• Shares granted: 2,500,000.
• Shares owned after transaction: not disclosed in this filing.
• Footnote: F1 — the shares were received as a grant under the company's Equity Incentive Plan.
• No indication of a 10b5-1 plan, sale, exercise, tax withholding, or late filing in this report.

Context

• Equity grants to executives are commonly used for compensation, retention, and aligning management with shareholder interests; they do not necessarily indicate the insider's short-term view of the stock.
• Because no exercise or sale occurred, this grant increases potential future ownership but may be subject to vesting or other restrictions (not specified in this filing).